Gyrasol Technologies, based in Lawrence, KS, was formed in 2007 to meet biopharmaceutical researchers’ urgent need for expertly designed drug selection assay technologies. We have discovered and developed novel sensors that enable simultaneous monitoring of protein kinase, lipid kinase, phosphatase, protease and phosphodiesterase activities in small biological sample sizes. The platform provides assays for the pharmaceutical industry which can be utilized throughout the drug development process.
In conjunction, Gyrasol is developing diagnostic applications of its core technologies to advance diagnostic products that can be used in conjunction with targeted therapeutics to enable personalized medicine.
Management
Susan K. Burgess, Ph.D., Founder, President and CEO, Chair
Frauke Rininsland, Ph.D., Founder, CSO, Director
Richard B. Murray, CFO
David J. Hayes, Ph.D., VP of Business Development
Directors and Advisors
Timothy J.R. Harris, Ph.D., Founder
Lynda Wijcik, Director
Roger Brent, Ph.D., Advisor
Charles Cantor, Ph.D., Advisor
David Slack, M.B.A., Advisor